TMCnet News
Med-eMonitor Compliance-Monitoring System Featured at 44th Annual NCDEU Meeting ROCKVILLE, Md. --(Business Wire)-- June 14, 2004 -- InforMedix, Inc. (OTC BB: IFMX) briefed key mental health experts on its Med-eMonitor(TM) web-based compliance-monitoring system during an executive session of industry thought leaders at the 44th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting, held June 1-4 in Phoenix, AZ. The annual conference, attended by over 1,240 attendees, was the second highest attended in the history of the NCDEU meeting. NCDEU is a scientific conference sponsored by the National Institute of Mental Health (NIMH) which brings together academic psychiatrists, psychologists, research pharmacists and nurses, investigators from the pharmaceutical industry, and representatives from the NIMH, the FDA and other government health agencies interested in psychopharmacology and the broader areas of interventions and services research."The breakfast meeting was part of the two-step process to launch the Med-eMonitor System this year," said Janet Campbell, president and COO of InforMedix. Hosted by InforMedix, attendees were briefed on the hand-held device's medication-dispensing system, as well as its ability to gather and upload patient data to secure databases. They also reviewed Med-eMonitor's recent successes in significantly improving medication compliance in clinical studies -- notably a National Institutes of Health-sponsored study of patients with chronic schizophrenia, the findings of which were published in the peer-reviewed Drug Information Journal (DIJ), the official publication of the Drug Information Association (DIA). The Med-eMonitor System is the only technology specifically designed to capture electronic patient reported outcomes (ePRO) in clinical trials. According to CenterWatch, the industry's source for information about clinical research, ePRO is the fastest growing segment of electronic data capture in drug trials, and industry sources estimate that ePRO will reach $3 billion in revenue by the end of 2005. ePRO Crucial to Assuring Validity of Future Clinical Trials Improvements in patient compliance and overall protocol-adherence are critical to the future of organized patient trials. This is especially important in light of recent reports indicating that the vast majority of patients fail to take their medications at proper times during clinical trials, in addition to incorrectly stating when they ingest their drugs, and their reaction to the drugs. Such misreporting calls into question the validity of large organized clinical trials. It is believed ePRO solutions can greatly aid in verifying patient compliance which will strengthen the validity of increasingly expensive patient trials. Med-eMonitor Solution Tailored to Patient Populations "Med-eMonitor is the only fully integrated ePRO device designed expressly for patients, many of whom have difficulty using other hand-held devices, which offer user interfaces originally designed for young consumers," noted InforMedix chairman and CEO Bruce A. Kehr, M.D. "Med-eMonitor's real-time medical management and patient communications can significantly enhance trial outcomes and patient safety, and correlate medication compliance with the clinical response of the patient." According to Campbell, "Over 30 mental healthcare thought leaders were introduced to our next generation 'e-diary' solution that helps ensure patients are taking their test medications as claimed. The FDA has now approved drugs that have relied on studies using electronic monitoring to help determine safety and efficacy. The market is clearly ready for an ePRO solution such as the Med-eMonitor." Alexander Miller, M.D., Professor of Psychiatry at the University of Texas Health Science Center, San Antonio, TX and a consultant to InforMedix in developing advanced patient-care protocols, said, "Those who saw the Med-eMonitor demonstrated agreed that it had significant potential not only for delivering high quality data in outpatient drug trials, but for enhancing patient protocol adherence and retention. Eventually, it is believed that Med-eMonitor can aid in the medication-management of long-term illnesses as well as improve the validity and safety of patient drug studies." About InforMedix InforMedix has developed the Med-eMonitor System to provide real-time medical management and patient communications for clinical drug trials. The Company has integrated a portable patient-interactive monitoring device, hardware, software and networked communications system to enable pharmaceutical and biotechnology companies, and medical researchers to efficiently monitor and manage patients' medication compliance, protocol adherence, clinical response, and safety. Med-eMonitor is specifically designed to improve patient medication compliance and protocol adherence in clinical drug trials. The Med-eMonitor System leverages InforMedix's strong intellectual property consisting of 15 issued patents and 14 patents pending. The Company's patents have been cited as prior art by patent examiners in over 150 other issued patents. Safe Harbor Provisions This report contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. References made to the discussion of the risk factors are detailed in the Company's filings with the Securities and Exchange Commission, including the report on Form 10-QSB for the quarter ended March 31, 2004, our Annual Report on Form 10-KSB for the year ended December 31, 2003, our prospectus dated May 28, 2004, and our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise. |
